Cargando…
Nuclear Imaging Study of the Pharmacodynamic Effects of Debio 1143, an Antagonist of Multiple Inhibitor of Apoptosis Proteins (IAPs), in a Triple-Negative Breast Cancer Model
BACKGROUND: Debio 1143, a potent orally available SMAC mimetic, targets inhibitors of apoptosis proteins (IAPs) members and is currently in clinical trials. In this study, nuclear imaging evaluated the effects of Debio 1143 on tumor cell death and metabolism in a triple-negative breast cancer (TNBC)...
Autores principales: | Bellaye, Pierre-Simon, Oudot, Alexandra, Vrigneaud, Jean-Marc, Raguin, Olivier, Bichat, Francis, Vaslin, Anne, Maby-El Hajjami, Hélène, Zanna, Claudio, Vuagniaux, Grégoire, Fumoleau, Pierre, Denat, Franck, Brunotte, François, Collin, Bertrand |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305031/ https://www.ncbi.nlm.nih.gov/pubmed/30627061 http://dx.doi.org/10.1155/2018/8494031 |
Ejemplares similares
-
Exploratory window‐of‐opportunity trial to investigate the tumor pharmacokinetics/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer
por: Gomez‐Roca, Carlos, et al.
Publicado: (2021) -
DEBIO 1143, an IAP inhibitor, reverses carboplatin resistance in ovarian cancer cells and triggers apoptotic or necroptotic cell death
por: Thibault, Benoît, et al.
Publicado: (2018) -
Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study
por: Hurwitz, Herbert I., et al.
Publicado: (2015) -
The inhibitor apoptosis protein antagonist Debio 1143 Is an attractive HIV-1 latency reversal candidate
por: Bobardt, Michael, et al.
Publicado: (2019) -
The inhibitor of apoptosis proteins antagonist Debio 1143 promotes the PD-1 blockade-mediated HIV load reduction in blood and tissues of humanized mice
por: Bobardt, Michael, et al.
Publicado: (2020)